PHO Share Price Performance
NOK 69.00
5.10 (7.98%)
16.4% undervalued intrinsic discount
NOK 82.50
Fair Value
Price NOK 69.00
AnalystConsensusTarget NOK 82.50
Fair ValueNOK 82.50
Share Pricen/a
Photocure ASA Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
PHO Community Narratives
AN
Fair Value NOK 82.5 16.4% undervalued intrinsic discount
Adoption Of ForTec’s Mobile Strategy Will Increase Market Penetration In The US
1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Adoption Of ForTec’s Mobile Strategy Will Increase Market Penetration In The US
Key Takeaways Expanding blue light cystoscopy in Europe and the U.S. through strategic initiatives is expected to enhance market access and drive revenue growth. Success in partnerships and technology launches is likely to fuel growth, while regulatory reclassification and approvals could unlock new revenue streams.Read more
65
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
NOK 82.5
16.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
7.69% p.a.
Profit Margin
9.6%
Future PE
38.61x
Price in 2028
NOK 97.35
Trending Discussion
Recently Updated Narratives
AN
Adoption Of ForTec’s Mobile Strategy Will Increase Market Penetration In The US
Fair Value: NOK 82.5 16.4% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Photocure ASA Key Details
About PHO
- Founded
- 1993
- Employees
- 100
- CEO
- WebsiteView website
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf’s System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.